KIMACEF

Treatment of infections caused by susceptible to cefuroxime by microorganisms or therapy to determine the infectious agent. Infectious diseases of the respiratory tract: acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, postoperative infections of the chest; infectious diseases of the nose and throat: sinusitis, tonsillitis, pharyngitis; infectious diseases of the urinary tract: acute and chronic pyelonephritis, cystitis, asymptomatic bacteriuria; infectious diseases of soft tissues: cellulites, erysipeloid, wound infection; infectious diseases of joints and bones: osteomyelitis, septic arthritis; infections in obstetrics and gynecology: an infectious-inflammatory diseases of the pelvic organs; gonorrhoea, especially in those cases when penicillin is contraindicated; other infectious diseases, including septicemia and meningitis. Prevention of infectious complications after operations on the thorax and abdomen, operations on the pelvic organs, vascular, cardiovascular and orthopedic operations. In most cases, monotherapy drug Kimacef is an effective, but if necessary, the drug can be used in combination with aminoglycoside antibiotics, or metronidazole (oral, rectal suppositories or injectable).In the case of existing or anticipated mixed aerobic and anaerobic infections (e.g., peritonitis, aspiration pneumonia, lung abscess, pelvic and brain) and the high incidence of such infections (e.g., in operations on the colon and gynecological surgery) acceptable is the drug of Kimacef in combination with metronidazole. In the treatment of pneumonia and exacerbation of chronic bronchitis drug Kimacef can be administered prior to oral application of the cefuroxime axetil when needed.